Merck (MRK) is back in focus after a Phase 3 study of intismeran autogene with Keytruda met its primary endpoints in melanoma, validating meaningful clinical benefits and reshaping how investors think about the stock’s long term opportunity.

Merck’s recent melanoma data hit just as momentum in the stock has picked up, with a 30 day share price return of 17.08% and a 90 day share price return of 27.70% contributing to a 1 year total shareholder return of 88.20% from a last close of US$153.10. This signals that investors are reassessing both the growth potential of the oncology pipeline and the risks around future patent expiries.

Ride Merck’s surge in oncology optimism and scan a curated 40 healthcare AI stocks that are also trying to turn cutting-edge science into durable shareholder returns.

Merck now trades slightly above the average analyst target, yet still screens at a sizeable discount to some intrinsic value estimates. After this sharp re rating, is the market’s caution on melanoma and patent risk actually misplaced?

Most Popular Narrative: 11.9% Overvalued

Compared with the last close of US$153.10, the most followed Merck narrative points to a fair value of US$136.85, which implies a premium in the current share price and puts fresh attention on what needs to go right in the business for that valuation gap to close.

With its acquisition and licensing strategy, Merck has nearly tripled its late phase pipeline since 2021, which is expected to have a potential commercial opportunity of over $50 billion by the mid 2030s, driving earnings growth. The ongoing strong launches of key new products, such as WINREVAIR and CAPVAXIVE, are positively impacting revenues and are expected to support further growth in the coming years.

Want to see the full playbook behind that fair value? The narrative leans on steady top line expansion, sharply higher margins and a richer earnings multiple. Curious which of those assumptions does the heavy lifting? The detailed breakdown is where those moving parts really start to matter.

Result: Fair Value of US$136.85 (OVERVALUED)

However, Merck’s story can shift quickly if GARDASIL softness in China persists or if KEYTRUDA’s eventual loss of exclusivity hits harder than analysts currently model.

Another View: Merck Through The SWS DCF Lens

The earlier Merck narrative framed the stock as 11.9% overvalued against a US$136.85 fair value. The SWS DCF model points in the opposite direction. It suggests Merck at US$153.10 trades around 34.3% below an estimated future cash flow value of US$232.91. This raises the question of which set of assumptions you trust more.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Merck for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment on Merck clearly mixed, you can move faster than the crowd by reviewing the full risk and reward picture and deciding what feels justified for your own portfolio using the 2 key rewards and 5 important warning signs.

Looking for more ideas beyond Merck?

Once you have formed a view on Merck, do not stop there. Broaden your opportunity set and stress test your thinking across different types of stocks using the Simply Wall Street Screener.

• Target quality at a discount by scanning a curated 51 high quality undervalued stocks that match strong fundamentals with appealing valuations.
• Prioritise peace of mind and focus on 75 resilient stocks with low risk scores that show more resilient characteristics across multiple risk factors.
• Hunt for tomorrow’s potential leaders before they gain wider attention by filtering for 20 high quality undiscovered gems with solid underlying metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.